Evidence map›Paper›PMID 40676595›Full record

Trial reportJournal of orthopaedic surgery and research2025

Timing optimization of teriparatide dosing for postmenopausal osteoporosis: a randomized controlled trial.

Huan Wang, Liyuan Tao, Dongyang Liu, Xiaoyan Yan, Haiyan Li, Chunli Song

Registry-linked trialAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of orthopaedic surgery and research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06951776 (Chronotherapeutic Optimization of Teriparatide Administration in Postmenopausal Osteoporosis), which is not on this map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06951776 nanot yet recruitingnot on this map

Chronotherapeutic Optimization of Teriparatide Administration in Postmenopausal Osteoporosis: A Randomized Controlled Exploratory Study

TypeinterventionalSponsorPeking University Third HospitalRan2025 to 2025Enrolled28ConditionsCircadian Rhythm Disorders, OsteoporosisArmsMorning administration group of teriparatide, Evening administration group of teriparatide
3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Huan WangDepartment of Orthopedics, Peking University Third Hospital, Beijing, China.
Liyuan TaoResearch Center of Clinical Epidemiology, Peking University Third Hospital, Beijing, China.
Dongyang LiuDrug Clinical Trial Center, Peking University Third Hospital, Beijing, China.
Xiaoyan YanClinical Research Institute, Peking University, Beijing, China.
Haiyan LiDrug Clinical Trial Center, Peking University Third Hospital, Beijing, China.
Chunli SongDepartment of Orthopedics, Peking University Third Hospital, Beijing, China. schl@bjmu.edu.cn.

Funding

National Key Research and Development Program 2021YFC2501700National Natural Science Foundation of China 82330078
6 · The paper itself

Abstract

backgroundAccumulating evidence highlights the critical role of circadian rhythms in regulating bone turnover. Bone turnover markers, including parathyroid hormone, C-terminal telopeptide of type I collagen, and N-terminal propeptide of type I procollagen, all exhibit distinct diurnal variations. Teriparatide, a recombinant parathyroid hormone analog, demonstrates time-dependent efficacy influenced by these endogenous rhythms. However, the impact of administration timing on bone metabolism remains underexplored.

objectiveThis randomized, open-label, exploratory trial investigates the impact of teriparatide administration timing by comparing subcutaneous injection at 08:00 versus 20:00 on bone turnover markers in postmenopausal women with osteoporosis.

methodsTwenty-eight participants (aged 60-70 years, lumbar spine T-score ≤ -3.0) will be randomized in a 1:1 ratio to receive 20 µg/day of teriparatide via subcutaneous injection at either 08:00 or 20:00 for 12 weeks. All participants will receive standardized calcium (1000-1500 mg/day) and cholecalciferol (800-1200 IU/day) supplementation throughout the study period. The primary outcomes are the between-group differences in serum parathyroid hormone, C-terminal telopeptide of type I collagen, and N-terminal propeptide of type I procollagen profiles, which will be assessed at baseline, 4 weeks, and 12 weeks. Secondary outcomes will evaluate the safety profile during the trial. DISCUSSION: This trial is expected to provide crucial insights into optimizing teriparatide administration timing, potentially guiding personalized dosing strategies to enhance bone formation and reduce fracture risk in osteoporosis. The findings may inform future research on circadian rhythm-aligned therapies.

trial registrationClinicalTrials.gov ID NCT06951776.

Indexed as

Bone Density Conservation AgentsOsteoporosis, PostmenopausalTeriparatideAgedBiomarkersBone RemodelingCircadian RhythmCollagen Type IDrug Administration ScheduleFemaleHumansInjections, SubcutaneousMiddle AgedParathyroid HormoneProcollagenRandomized Controlled Trials as TopicBiomarkersBone Density Conservation AgentsCollagen Type IParathyroid HormoneProcollagenTeriparatideBone turnover markersCircadian rhythmPostmenopausal osteoporosisTeriparatideTiming

Identifiers

PMID40676595
PMCPMC12273002

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.